NCT00016237View on ClinicalTrials.gov

Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

December 31, 2000

Conditions
Bladder CancerKidney CancerLung Cancer
Interventions
BIOLOGICAL

tucotuzumab celmoleukin

Trial Locations (2)

10021

Memorial Sloan-Kettering Cancer Center, New York

20007

Lombardi Cancer Center, Washington D.C.

Sponsors

Lead Sponsor

EMD Serono
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Memorial Sloan Kettering Cancer Center

OTHER

lead

EMD Serono

INDUSTRY

NCT00016237 - Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment | Biotech Hunter | Biotech Hunter